Abstract:Abstract Lung cancer is one of the most common malignancies worldwide with non-small cell lung cancer (NSCLC) being the dominant subtype. Surgical resection remains the best treatment for NSCLC, but late diagnosis with associated metastasis precludes this as a viable modality for most patients. Furthermore, other treatments such as targeted therapies, cytotoxics, and immunotherapy only benefit a minority of patients. Therefore, new therapeutic strategies are needed to benefit more patients presenting with this devastating disease. Recent studies reveal that DNMT inhibitor (DNMTi) promotes tumor-infiltrative cytotoxic CD8+ T cells, shifts myeloid-derived suppressor cells (MDSCs) to anti-tumor macrophage-like phenotype, and enhances immunotherapy efficacy. However, some immune-regulatory genes are silenced by H3K27me3, which is facilitated by the transcriptional repressor EZH2. Additionally, conditional ablation of Ezh2 in T cells boosts effector functions of CD8+ T cells and prevents the development of regulatory T cells. Given the above, the application of combining DNMTi and EZH2i might be a viable path to facilitate tumor immune microenvironment remodeling. In this study, we aimed to define the therapeutic potential of combining DNMT and EZH2 inhibition to facilitate an anti-tumor immune response. First, we explored the potential of combined DNMTi and EZH2i in a clinically relevant murine model of NSCLC, Lewis Lung Carcinoma 1 (LLC1). Therapeutic application in this model led to a significant reduction in tumor volume. Our transcriptomic data revealed DNMTi facilitated transcriptional perturbation of both coding and transposable element-related genes, which is driven further by EZH2i combination. Immune deconvolution analysis uncovers combination therapy-induced shifts in tumor immune-cellularity, which is most profound for myeloid-associated populations. Orthogonal validation by flow cytometry defines significant reductions of MDSCs and regulatory T cells occurring within the tumor and associated microenvironment. Given the perturbations of T and myeloid cells observed in-vivo, we sought to define the drug effects on critical cell populations contained in these lineages. These data revealed that combining DNMTi and EZH2i promotes effector CD8+ T cells with more IFN-g secretion upon activation but halts the cells from exhaustion after chronic stimulation. Moreover, co-treatment promoted maturation, cross-presentation, and antigen-specific CD8+ T cell priming in dendritic cells (DCs). These data indicate that CD8+ T cells and DCs subjected to co-treatment might facilitate more robust tumor immune responses in the tumor microenvironment (TME). In summary, our data define an effective therapeutic paradigm for the treatment of NSCLC, which potentiates significant shifts in TME resident immune populations and dendritic cell phenotypes. Citation Format: Ying-Yu Chen. Modulating DNA and histone methylation as a therapeutic target for non-small cell lung cancer by shifting the composition of immune cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3480.

A Novel Small Molecular Inhibitor of DNMT1 Enhances the Antitumor Effect of Radiofrequency Ablation in Lung Squamous Cell Carcinoma Cells

Abstract 1397: the Regulation of DNMT3B Expression by Lncrna-Ncrms in Cancer

MicroRNA-145 Inhibits Growth of Laryngeal Squamous Cell Carcinoma by Targeting the PI3K/Akt Signaling Pathway.

The Loss-of-function of DNA Methyltransferase 1 by Sirna Impairs the Growth of Non-Small Cell Lung Cancer with Alleviated Side Effects Via Reactivation of RASSF1A and APC in Vitro and Vivo.

MicroRNA-9 Enhanced Radiosensitivity and Its Mechanism of DNA Methylation in Non-Small Cell Lung Cancer

Radiosensitization effect of hsa-miR-138-2-3p on human laryngeal cancer stem cells.

KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer

Long noncoding RNA <i>LINC00518</i> induces radioresistance by regulating glycolysis through an miR-33a-3p/HIF-1 negative feedback loop in melanoma

Downregulation of DNMT3A by miR-708-5p Inhibits Lung Cancer Stem Cell-like Phenotypes through Repressing Wnt/beta-catenin Signaling

Long noncoding RNA LINC00518 induces radioresistance by regulating glycolysis through an miR-33a-3p/HIF-1α negative feedback loop in melanoma.

Long Noncoding RNA LINC00958 Regulates Cell Sensitivity to Radiotherapy Through RRM2 by Binding to Microrna‐5095 in Cervical Cancer

Melatonin Enhances the Remote Effect of Radiofrequency Ablation Via NRF-2 Mediated Inhibition of PD-L1 Transcription in Non-Small Cell Lung Cancer

Critical Role of Delta Dnmt3b4/2 in Regulating Rassf1a Promoter-Specific Dna Methylation in Non-Small Cell Lung Cancer

Overexpression of DNMT1 Accelerates Migration and Invasion of Lung Squamous Cell Carcinoma Cells by Decreasing TCF21 Expression Via the Akt/p65 Signaling Pathway

RNA Interference-Mediated Knockdown of DNA Methyltransferase 1 Leads to Promoter Demethylation and Gene Re-Expression in Human Lung and Breast Cancer Cells

Data from Downregulation of DNMT3A by Mir-708-5p Inhibits Lung Cancer Stem Cell–like Phenotypes Through Repressing Wnt/β-catenin Signaling

Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer

Methylenetetrahydrofolate Dehydrogenase 1 Silencing Expedites the Apoptosis of Non-Small Cell Lung Cancer Cells Via Modulating DNA Methylation

Microrna-342 Inhibits Colorectal Cancer Cell Proliferation and Invasion by Directly Targeting Dna Methyltransferase 1

Abstract 3480: Modulating DNA and Histone Methylation As a Therapeutic Target for Non-Small Cell Lung Cancer by Shifting the Composition of Immune Cells

Inhibition of DNMTs increases neoantigen-reactive T-cell toxicity against microsatellite-stable colorectal cancer in combination with radiotherapy